Biotech

10/27/23

A going concern clause isn’t always a concern

Biotech

Finance

10/20/23

Everything you’ve always wanted to ask an Audit Committee member (but were too afraid to ask)

Biotech

Finance

09/19/23

Why we’re stuck on Hyku Biosciences

Biotech

Finance

Science

08/24/23

Shutting down Silverback — a Q&A with Laura Shawver

Biotech

Finance

05/05/23

Do we value curbing carbon emissions more than curing cancer?

Biotech

Policy

05/03/23

Toxic math: a British export that the US mustn’t import

Biotech

Policy

03/23/23

Why fixing the IRA matters to all of us

Biotech

Policy

03/17/23

Woah! Are Phase 3s no longer enough for CMS?

Biotech

Finance

03/12/23

Act now to prevent SVB’s failure from becoming a national crisis

Biotech

Finance

Policy

Planetary

03/10/23

A crisis we don’t need: How not to cause a bank run

Biotech

Finance

02/09/23

FutureCast | Time to Reboot Biotech

Biotech

Finance

01/20/23

So you want to be a TechAtlas intern…

Biotech

Culture

01/13/23

Is ChatGPT smarter than Congress?

Biotech

Culture

01/03/23

Semper Maior: Time to Reboot Biotech

Biotech

Finance

12/12/22

FutureCast | Back to the future: How old drugs are enabling new discoveries and a new era for treating depression

Biotech

Science

12/08/22

Getting animated about GCEA

Biotech

Policy

11/22/22

I walked 100 miles for this term sheet

Biotech

Culture

Finance

11/16/22

Transforming Forma — The Science of Giving a Damn

Biotech

Culture

Finance

10/31/22

Alnylam is doing what the IRA is telling it to do

Biotech

Finance

Policy

09/21/22

Saving money for Medicare by abandoning new drugs for Medicare patients

Biotech

Finance

Policy